Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
37 Results for "
atherosclerotic lesion
" in MedChemExpress (MCE) Product Catalog:
Products (37)
37 Results for "atherosclerotic lesion" in MCE Product Catalog:
3
3 Cited Publications
Cat. No.: HY-19900
CAS No.: 1252679-52-9
Research Areas:
ITX5061 is an orally active type II non-competitive p38 MAPK inhibitor. ITX5061 increases HDL-C levels by inhibiting SR-BI activity. ITX5061 also moderately elevates ApoA-I levels. ITX5061 reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 can be used in the research of atherosclerosis .
Cat. No.: HY-B0374
CAS No.: 75438-57-2
Synonyms: BDF5895
Research Areas:
Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .
Cat. No.: HY-B0374A
CAS No.: 75536-04-8
Synonyms: BDF5895 hydrochloride
Research Areas:
Moxonidine (BDF5895) hydrochloride is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine hydrochloride activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine hydrochloride reduces atherosclerotic lesions and lowers blood pressure. Moxonidine hydrochloride can be used in the study of hypertension, heart failure, and atherosclerosis .
Research Areas:
Melagatran is a reversible, selective, orally active direct inhibitor of thrombin with a Ki of 2 nM. Melagatran binds directly to the active site of thrombin, inhibiting thrombin-mediated conversion of fibrinogen to fibrin. Melagatran reduces the DNA binding activity of NF-κB and AP-1. Melagatran reduces fibrin deposition in organs, alleviates ischemic brain damage, and reduces the size of advanced atherosclerotic lesions. Melagatran can be used in the study of cardiovascular disease (coronary thrombosis, atherosclerosis) and ischemic brain damage .
Cat. No.: HY-162562
CAS No.: 930017-01-9
Target:
Research Areas:
E28362 is an orally active lipid-lowering agent and a selective PCSK9 antagonist. E28362 blocks the interaction between PCSK9 and LDLR, and induces PCSK9 degradation via the ubiquitin-proteasome pathway. E28362 significantly increases the levels of cell surface and total LDLR proteins, enhances low-density lipoprotein uptake, thereby effectively reducing plasma lipids, hepatic cholesterol and triglyceride levels. E28362 shows no obvious cytotoxicity at high concentrations, and significantly attenuates atherosclerotic lesions in animal models. E28362 is an important molecule in research of hyperlipidemia and atherosclerosis .
Cat. No.: HY-N13250
Research Areas:
4-CPPC is a selective MIF-2 inhibitor with a Ki of 33 µM. 4-CPPC inhibits the COX2/PGE2 pathway, reduces the levels of COX2 and mPGES-1, and decreases the production of PGE2. 4-CPPC attenuates the formation of early atherosclerotic lesions in hyperlipidemic mice, and lowers the levels of circulating inflammatory cytokines and chemokines. 4-CPPC inhibits MIF-2-triggered cell migration. 4-CPPC improves hindlimb motor function in rats with contusion-induced spinal cord injury. 4-CPPC can be used in studies related to atherosclerosis and spinal cord injury .
Cat. No.: HY-144012A
CAS No.: 474922-84-4
Synonyms: 16:0 PEG350 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium
Target:
Research Areas:
DPPE-PEG350 (16:0 PEG350 PE) is a CD1d lipid antagonist. DPPE-PEG350 blocks alpha-GalCer-dependent ERK tyrosine kinase phosphorylation in cells. DPPE-PEG350 inhibits cellular IL-4 and IFN-gamma production following alpha-GalCer stimulation. DPPE-PEG350 selectively antagonizes iNKT without affecting MHC class II-dependent OVA-specific Th2 responses. DPPE-PEG350 reduces MCP-1 and VCAM-1 protein expression and necrotic core formation in atherosclerotic lesions. DPPE-PEG350 can be used for research on asthma and atherosclerosis .
Cat. No.: HY-W996116
CAS No.: 1933460-23-1
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
AZM198 is an orally active myeloperoxidase (MPO) inhibitor. AZM198 irreversibly inactivates MPO (IC50=0.015 μM) via covalent binding to the heme prosthetic group, preferentially targets extracellular MPO activity, and reduces neutrophil extracellular trap formation, reactive oxygen species production and degranulation. AZM198 increases the fibrous cap thickness of atherosclerotic plaques, reduces lesion area, ameliorates hepatic steatosis and fibrosis in non-alcoholic steatohepatitis, and alleviates proteinuria and inflammatory infiltration associated with glomerulonephritis. AZM198 also decreases circulating levels of high-sensitivity Cardiac Troponin I and IL-1β, and mitigates endothelial cell injury. Therefore, AZM198 is suitable for research on various MPO-related diseases, including atherosclerotic cardiovascular disease, myocardial infarction, ischemic stroke, non-alcoholic steatohepatitis and crescentic glomerulonephritis .
Target:
Cat. No.: HY-129440R
CAS No.: 68573-24-0
Cat. No.: HY-W013812R
CAS No.: 544-35-4
Synonyms: Linoleic Acid ethyl ester (Standard); Mandenol (Standard)
Category:
Target:
Cat. No.: HY-B0374S
CAS No.: 1794811-52-1
Cat. No.: HY-W013812S
CAS No.: 202114-63-4
Synonyms: Linoleic Acid-13C18 ethyl ester; Mandenol-13C18
Cat. No.: HY-130587
CAS No.: 57775-27-6
Synonyms: Piperazine sultosylate; A-585
Target:
Research Areas:
Sultosilic acid piperazine salt (Piperazine sultosylate; A-585) is a lipid-lowering agent. Sultosilic acid piperazine salt modifies the blood lipids levels, reduces platelet adhesiveness without promoting peroxisomal activity of hepatocytes or producing other adverse side-effects .
Cat. No.: HY-W013812S1
CAS No.: 1169764-57-1
Synonyms: Linoleic Acid ethyl ester-d5; Ethyl linoleate, pure-d5; Mandenol-d5
Target:
Research Areas:
Ethyl linoleate-d5 (Linoleic Acid ethyl ester-d5) is deuterium labeled Ethyl linoleate. Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators .
.
.
Cat. No.: HY-123016
CAS No.: 143442-54-0
Target:
Research Areas:
9(S)-HODE cholesteryl ester is originally extracted from atherosclerotic lesions. It remains uncertain whether the oxidized fatty acid portion of the molecule results from enzymatic lipoxygenation or from random lipid peroxidation.2 9(S)-HODE cholesteryl ester can be used as a standard for analysis of chiral HODE cholesteryl esters.
Cat. No.: HY-125394
CAS No.: 330800-93-6
Target:
Research Areas:
9(R)-HODE cholesteryl ester is originally extracted from atherosclerotic lesions. It remains uncertain whether the oxidized fatty acid portion of the molecule results from enzymatic lipoxygenation or from random lipid peroxidation.2 9(R)-HODE cholesteryl ester can be used as a standard for analysis of chiral HODE cholesteryl esters.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
